

FIRST ORAL VACCINE FOR PREVENTING GIARDIASIS

KEYWORDS


Giardia, Diarrheal Disease, Extracellular Vesicles (EVs), Oral Vaccine

TECHNOLOGY DESCRIPTION

Extracellular vesicle-based oral vaccine for the prevention of giardiasis, namely Diarrheal Disease, an infection caused by the protozoa *Giardia lamblia* (also known as *Giardia intestinalis* or *Giardia duodenalis*)

Problem to tackle:

- ~1.7 billion cases of diarrheal disease are reported globally each year
- Diarrheal disease is the 2^o leading cause of death worldwide
- Loss of worker productivity and direct impact on healthcare systems



The first, oral, and stable vaccine for the prevention of giardiasis

ADVANTAGES OVER ALTERNATIVE TECHNOLOGIES

In humans and animals:

- No vaccine to prevent giardiasis, in animals (dogs) the only one was discontinued
- Oral administration route (no need for injection)
- Stable formulation (easy to transport and store)
- Used as a preventive method rather than a therapeutic strategy

APPLICATIONS

Prevention of giardiasis in humans and animals and use as adjuvant of other vaccines to treat infection diseases

PATENT SPECIFICATIONS

Reference: PCT/IB2022/057466

Responsible Inventor: [Maria do Céu Sousa](#) ([Medicinal Chemistry and Drug Discovery](#))

Applicants: University of Coimbra ([Center for Neuroscience and Cell Biology](#))

CONTACTS

Center for Neuroscience and Cell Biology - [Technology Transfer Office](#)

Catarina Cunha Santos, PhD - TTO

Phone: +351 239 820 190

E-mail: techtransfer@cnc.uc.pt